Pregled bibliografske jedinice broj: 1259912
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG) // Cardiovascular Diabetology, 16 (2017), 1; 137-147 doi:10.1186/s12933-017-0622-7 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1259912 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Translating recent results from the Cardiovascular
Outcomes Trials into clinical practice:
recommendations from the Central and Eastern
European Diabetes Expert Group (CEEDEG)
Autori
Schernthaner, Guntram ; Lehmann, Roger ; Prázný, Martin ; Czupryniak, Leszek ; Ducena, Kristine ; Fasching, Peter ; Janež, Andrej ; Karasik, Avraham ; Kempler, Peter ; Martinka, Emil ; Shestakova, Marina V. ; Duvnjak, Lea Smirčić ; Tankova, Tsvetalina
Izvornik
Cardiovascular Diabetology (1475-2840) 16
(2017), 1;
137-147
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Keywords: Anti-glycaemic drugs ; Cardiovascular disease ; Renal disease ; Type 2 diabetes
Sažetak
Aims: These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD) are major interdependent comorbidities in patients with T2D, accounting for 50% of mortality. Following recent CV outcomes trial (CVOT) results, including those from EMPA-REG OUTCOME®, LEADER®, SUSTAIN™-6 and, most recently, the CANVAS study, it is essential to develop regional expert consensus recommendations to aid physicians in interpreting these newest data to clinical practice. Methods: The Central and Eastern European Diabetes Expert Group (CEEDEG) followed a Delphi method to develop treatment algorithms to aid physicians in the clinical management of patients with T2D at high CV risk. Results: In light of the latest CVOT results, and in particular the EMPA-REG OUTCOME® and LEADER® trials, the diagnosis, assessment, treatment choice and monitoring of patients with T2D and established CVD and/or CKD have been considered together with existing guidelines and presented in two reference algorithms. In addition, adherence, special prescribing considerations and a proposed multidisciplinary management approach have been discussed and are presented with the proposed algorithms. Conclusions: The latest available high-level evidence on glucose-lowering drugs has enabled CEEDEG to develop practical consensus recommendations for patients with established CVD and/or CKD. These recommendations represent an update to international and country-level guidelines used for these patients, with the aim of providing a resource not only to endocrinologists, but to cardiologists, nephrologists and primary care physicians in the region.
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE